In-hospital costs of coronary stent implantation with and without eptifibatide (The ESPRIT trial)

被引：18

作者：

Cohen, DJ

O'Shea, JC

Pacchiana, CM

Levine, G

Sarembock, I

Slater, J

Conn, E

Smith, J

Tcheng, JE

机构：

[1] Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA

[2] Duke Clin Res Inst, Durham, NC USA

[3] Ben Taub Med Ctr, Houston, TX USA

[4] Univ Virginia, Hlth Syst, Charlottesville, VA USA

[5] St Lukes Roosevelt Hosp, New York, NY 10025 USA

[6] Mem Hosp, Chattanooga, TN USA

[7] St Vincents Hosp, Erie, PA USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2002年 / 89卷 / 01期

关键词：

D O I：

10.1016/S0002-9149(01)02165-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Among patients who underwent coronary stenting and were randomized to eptifibatide (n = 1,040) or placebo (n = 1,024), use of eptifibatide reduced initial procedural costs by $151/patient ($4,423 vs $4,574, p = 0.005) and costs related to ischemic complications by $61/patient ($283 vs $344, p = 0.002). When the cost of study drug was included, total initial hospital costs were increased by <$300/patient with eptifibatide compared with placebo ($10,632 vs $10,395, p <0.001).

引用

页码：61 / +

页数：5